Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenetic upregulation of Schlafen11 renders WNT- and SHH-activated medulloblastomas sensitive to cisplatin

21 Oct 2022

Abstract excerpt

BACKGROUND: Intensive chemotherapeutic regimens with craniospinal irradiation have greatly improved survival in medulloblastoma patients. However, survival markedly differs among molecular subgroups and their biomarkers are unknown. Through unbiased screening, we found Schlafen family member 11 (SLFN11), which is known to improve response to DNA damaging agents in various cancers, to be one of the top prognostic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glioma Diagnosis and Treatment
Share to Histone Deacetylase Inhibitors Research
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36273330
DOI: 10.1093/neuonc/noac243

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenetic upregulation of Schlafen11 renders WNT- and SHH-activated medulloblastomas sensitive to cisplatinPMID 36273330Read ↗

Subgroup-Specific Diagnostic, Prognostic, and Predictive Markers Influencing Pediatric Medulloblastoma TreatmentSemantic proximity Read ↗

The Neurodevelopmental and Molecular Landscape of Medulloblastoma Subgroups: Current Targets and the Potential for Combined TherapiesSemantic proximity Read ↗

New perspectives in the treatment of adult medulloblastoma in the era of molecular oncology.Semantic proximity Read ↗

Dissecting the genomic complexity underlying medulloblastoma.Semantic proximity Read ↗

Interrogation of SLFN11 in pediatric sarcomas uncovers an unexpected biological role and a novel therapeutic approach to overcoming resistance to replicative stressSemantic proximity Read ↗

Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological FeaturesSemantic proximity Read ↗

SLFN11 is Widely Expressed in Pediatric Sarcoma and Induces Variable Sensitization to Replicative Stress Caused By DNA-Damaging AgentsSemantic proximity Read ↗

Emerging treatments and gene expression profiling in high-risk medulloblastoma.Semantic proximity Read ↗

Genomics Identifies Medulloblastoma Subgroups That Are Enriched for Specific Genetic AlterationsSemantic proximity Read ↗

FSTL5 Is a Marker of Poor Prognosis in Non-WNT/Non-SHH MedulloblastomaSemantic proximity Read ↗

Medulloblastoma in Adults: Cytogenetic Phenotypes Identify Prognostic Subgroups.Semantic proximity Read ↗

Medulloblastoma molecular dissection: the way toward targeted therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.